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Mesenchymal stromal cells (MSCs) orchestrate tissue repair by releasing cell-derived 
microvesicles (MVs), which, presumably by small RNA species, modulate global gene 
expression. The knowledge of miRNA/mRNA signatures linked to a reparative status 
may elucidate some of the molecular events associated with MSC protection. Here, 
we used a model of cisplatin-induced kidney injury (acute kidney injury) to assess how 
MSCs or MVs could restore tissue function. MSCs and MVs presented similar protective 
effects, which were evidenced in  vivo and in  vitro by modulating apoptosis, inflam-
mation, oxidative stress, and a set of prosurvival molecules. In addition, we observed 
that  miRNAs (i.e., miR-880, miR-141, miR-377, and miR-21) were modulated, thereby 
showing active participation on regenerative process. Subsequently, we identified that 
MSC regulates a particular miRNA subset which mRNA targets are associated with Wnt/
TGF-β, fibrosis, and epithelial–mesenchymal transition signaling pathways. Our results 
suggest that MSCs release MVs that transcriptionally reprogram injured cells, thereby 
modulating a specific miRNA–mRNA network.
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•	 MSCs	modulate	 an	 internal	 regulatory	miRNA–mRNA	net-
work	that	is	associated	with	tissue	repair.
inTrODUcTiOn





repair	 (2).	 Functionally,	 MSC-derived	MVs	 (MSC-MVs)	 have	
the	potential	to	transfer	many	sources	of	molecular	information,	
including	non-coding	small	regulatory	RNAs,	which	can	induce	
a	pleiotropic	 effect	on	 target	 cells	 (3,	4).	Although	not	 entirely	
elucidated,	 the	 mechanism	 of	 transcriptional	 reprograming	 of	












of	 MSC-MVs.	 In	 a	 model	 of	 acute	 kidney	 injury	 (AKI),	 the	
infusion	of	MSC-MVs	promoted	the	activation	of	a	prosurvival	
program	 in	 injured	 tubular	 epithelial	 cells	 with	 reduction	 of	
apoptosis	 and	 improvement	 of	 cell	 proliferation	 rates	 via	 a	
horizontal	 transfer	of	RNAs	 (9,	10).	MSC-MVs	have	also	been	
tested	 in	 myocardial	 infarction	 models,	 where	 they	 reduced	
the	 necrotic	 area	 and	 enhanced	 blood	 flow	 recovery	 (11,	 12).	
Furthermore,	in	acute	lung	injury	models,	MSC-MV	treatment	
reduced	 pulmonary	 edema,	 hypertension,	 and	 lung	 protein	
permeability	and	suppressed	the	 innate	 inflammatory	response	
(13,	14).	Complementarily,	Zhang	 et  al.	 demonstrated	 that	 the	
graphical absTracT | de almeida et al. found that mesenchymal stromal cells via cell-derived microvesicles modulate a mirna/mrna network 
that is linked with Wnt/TgF-β, fibrosis, and epithelial–mesenchymal transition signaling pathways. The authors detected that mirnas mir-880, 
mir-141, mir-377, and mir-21 are modulated, and they can be associated to internal reprograming of tubular epithelial cells promoting tissue 
repair.
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injection	of	MSC-MVs	can	decrease	allograft	skin	rejection	via	a	
mechanism	that	is	dependent	on	Tregs	polarization	(15).	Other	
studies	 also	 identified	 that	MSC-MVs	 inoculation	 induced	 an	
efficient	 regeneration	 of	 sciatic	 nerve	 with	 the	 promotion	 of	





To	address	 this	 issue	and	clarify	some	of	 the	aspects	related	
to	 cell-based	 therapies	 for	 kidney	 diseases,	 we	 tested	 here	 the	












submitted	 to	 enzymatic	 digestion	by	 37°C	with	 collagenase	 IA	
0.1%	(Sigma,	USA).	In	sequence,	these	cells	were	filtered	in	cell	







adipogenesis,	 chondrogenesis,	 and	 osteogenesis	 Mesenchymal	
Stem	Cell	Kit	(Millipore,	USA),	according	to	the	manufacturer’s	
specifications	(n = 5).	For	MV	isolation,	the	24h	MSC	serum-free	







kit,	 strictly	 following	 the	 manufacturer’s	 instructions	 (Agilent	
Technologies,	 Santa	Clara,	 CA,	USA)	 (n =  5).	 Two	 additional	
groups	 consisting	 of	MVs	 treated	with	 RNAse	A	 (100  µg/mL,	
Thermo	Scientific,	USA)	and	ultracentrifuged	medium	without	
cells	were	carried	out	concomitantly,	and	all	samples	were	read	





recommendations	 (n  =  5).	 Briefly,	 cells	 were	 washed	 (PBS),	
centrifugated	(2,000 g	at	5 min),	and	incubated	(45 min	in	dark	
room)	 with	 specific	 antibody	 at	 1:100	 dilution	 and	 rewashed	
afterward	 in	FACs	buffer	 (PBS	2%	FBS).	A	FACSCanto	 II	flow	
cytometer	(BD,	Beckton	Dickson)	was	used	for	cell	acquisition,	
and	the	FlowJo	software	was	used	for	data	analysis.
coculture of Mscs or MVs with renal 
Tubular cells
For	 in  vitro	 assays,	 approximately	 2  ×  105	 of	 renal	 epithelial	
tubular	 cells	 (MM55.K,	ATCC®	CRL-6436TM)	were	 seeded	 in	






and	 oxidative	 stress	 analysis	 using	 the	 respective	 kits:	 Alexa	









distinguish	 the	 tubular	 cells	 population	 (MM55.K	 cells)	 from	











animal experiments and study groups
For	all	animal	experiments,	we	used	adult	C57BL/6	mice,	aged	
8–12 weeks	with	20–30 g	weight	(n = 8	per	group).	The	animals	
were	 housed	 in	 polypropylene	 boxes	 at	 controlled	 room	 tem-




three	 study	 groups	 according	 to	 the	 experimental	 procedures:	
mice	 treated	 with	 saline	 solution,	 mice	 treated	 with	 cisplatin,	
and	mice	treated	with	cisplatin	but	also	transplanted	with	MSCs	
or	MVs.
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performed	(n = 8	per	group).	The	control	group	was	administered	
with	300 µL	phosphate	buffer	(PBS).	After	24 h	of	cisplatin	treat-
ment	 (day +  1),	 1 ×  106	 of	MSCs	or	300 µL	of	 saline	 solution	
(Sham	 group)	 were	 infused	 intraperitoneally	 in	 the	 animals.	
Conforming	pre-established	by	our	 lab	 (data	not	 showed)	 and	
in	classical	works	in	the	literature	(6,	10),	around	100 µg	of	MVs	
suspension	was	infused	intravenously	on	day	+1	and	day	+3	after	




µL;	 Stratagene,	 USA);	 (ii)	 MVs	 pretreated	 with	 a	 cocktail	 of	
proteases	 [Proteinase	K	 20  µg/mL	 (Sigma,	USA),	 trypsin	 (Life	
Technologies,	USA)	and	collagenase	1 A	(Sigma,	USA)];	and	(iii)	
MVs	pretreated	with	Proteinase	K	20 µg/mL	(Sigma,	USA)	and	
RNase	 A	 (100 mg/mL;	Thermo	 Scientific,	 USA),	 according	 to	
the	manufacturer’s	instructions.	At	day	4	after	cisplatin	admin-
istration,	with	or	without	MSC	or	MV	infusion,	all	groups	were	




The	 creatinine,	 urea,	 and	 lactate	 analysis	 were	 performed	 to	
measure	 the	 status	 of	 renal	 function	 (n =  8).	 Creatinine	 was	
measured	using	the	Jaffe	modified	method	(Labtest	Diagnostic,	
Brazil).	Urea	concentration	was	analyzed	with	a	urea	kit	(Labtest	
Diagnostic,	 Brazil),	 according	 to	 the	 manufacturer’s	 specifica-
tions.	The	percentage	of	lactate	was	measured	using	Advia	1650	
equipment	 (Bayer,	 Germany),	 following	 the	 datasheet	 instruc-




histomorphometry of Kidney Tissue
Kidney	 fragments	 were	 fixed	 in	 buffered	 formaldehyde	 4%	
(pH =  7.0)	 and	 embedded	 in	 paraffin	 block.	 For	 each	 group,	
histological	 sections	of	4–5 µm	were	performed	and	 the	 slides	
were	stained	with	hematoxylin/eosin	(H&E).	For	a	quantitative	
evaluation	 of	 renal	 injury,	 clinical	 pathologic	 score	 of	 tissue	
damage	 was	 performed.	 Twenty-five	 fields	 from	 five	 slides	





was	 assigned	 for	 each	 parameter,	 according	 to	 injury	 severity	
(0 = absent,	1 = mild,	2 = moderate,	and	3 =  severe).	Finally,	
an	 overall	 percentage	 score	 (e.g.,	 arithmetic	mean	 of	 all	 abso-
lute	 parameters)	 was	 generated	 following	 a	 direct	 comparison	
between	the	experimental	groups.
In Situ immunostaining
Tissue	 sections	 of	 3–4  µm	 were	 processed	 on	 silanized	 slides	
(n  =  5).	 The	 immunohistochemistry	 was	 performed	 using	
protein	 block	 reagent,	 an	 EnVision+/HRP-Dual	 Link	 kit,	
DAB	 (3-3)	 tetrahydrochloride	 and	 diaminobenxidine	 solu-
tion	 (Dako, Denmark),	 and	caspase	3	 antibodies	 (1:1,000,	Cell	
Signaling,	 USA),	 following	 the	 manufacturer’s	 specifications.	







permeabilized,	 and	 incubated	with	primary	antibodies	 (1:200),	
i.e.,	 anti-Ki-67	 (Abcam,	USA),	 followed	by	 secondary	antibod-






tion	 contained	 in	 the	 manufacturer’s	 protocol.	 The	 following	
in situ	assays	such	as	(i)	renal	fibrosis	by	picrosirius	method,	(ii)	
cell	proliferation	(immunohistochemistry	to	Ki-67),	and	(iii)	cell	
death	 (immunohistochemistry	 to	 Caspase-3)	 were	 performed	
using	 the	 quantification	 of	 at	 least	 20–30	 fields	 (magnification	
200×)	with	software	developed	by	Nikon	(NIS	elements	micro-
scope	Nikon).
assessment of Oxidative stress and 
Determination of cytokines
The	 in  vivo	 tissue	 oxidative	 stress	 was	 evaluated	 indirectly	 by	
nitric	 oxide	 (NO)	 measurement	 using	 the	 Griess	 modified	
method	(n = 6).	In	addition,	the	renal	content	of	reduced	(GSH)	
and	 oxidized	 (GSSG)	 glutathione	 levels	 were	 assessed	 using	 a	
glutathione	fluorescent	detection	kit	 (BioVision,	USA),	 follow-
ing	 the	manufacturer’s	 instructions	 (n = 6).	The	animal	 serum	










(Thermo	 Scientific,	USA)	 and	Bioanalyzer	 equipment	 (Agilent	
Technologies,	USA)	(n = 6	per	group).	Furthermore,	the	reverse	
transcription	of	total	RNAs	and	miRNAs	was	performed	using,	
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all	 recommendations	 in	 datasheet	 (Qiagen,	 South	 Korea).	 For	
















network analysis of Differentially 
expressed mirnas and Their mrna 
Targets
Differentially	 expressed	 miRNAs	 were	 selected	 between	 the	
groups	using	the	QIAGEN	software	website	analysis.	Only	the	
miRNAs	that	had	at	least	fivefold	changes	in	expression	were	
included	 in	 further	 analysis.	 Furthermore,	 the	MIR@NT@N	
resource	 was	 used	 to	 identify	mRNAs	 that	 were	 targeted	 by	
the	 selected	 differentially	 expressed	miRNAs	 (18).	Then,	 we	
searched	 for	 overlaps	 in	 the	miRNA	 sets	 using	GeneVenn,	 a	
web	application	 for	comparing	 set	 lists	using	Venn	diagrams	
(19).	The	known	and	predicted	relationships	between	miRNAs	
and	 target	 genes	 were	 obtained	 from	 the	 DIANA	 Tools	 and	
MIR@NT@N	resource,	according	to	the	criteria	in	the	default	
parameters	 (18–21).	 We	 only	 selected	 those	 genes	 targeted	
by	 at	 least	 two	miRNAs	 to	 restrict	 our	 analysis	 to	 the	most	
relevant	 pairs	 of	 connected	miRNAs	 and	mRNAs.	 Pathways	






allows	 network	 editing	 and	 visualization	 of	 the	 molecular	
interactions	(22).




of	 RNA	 oligos,	 in	 order	 to	 inhibit	 or	 to	 overexpress	 specific	
miRNAs	 (i.e.,	miR-21,	miR-377,	miR-880,	 and	miR-141).	The	
cells	were	submitted	to	a	transfection	process	using	the	N-TER	










for	 electrophoresis	 on	 10%	 polyacrylamide	 gels	 (SDS-PAGE).	
The	 immunostaining	was	 carried	 out	 with	 primary	 antibodies	

















differences,	 respectively,	 between	 two	 or	 more	 independent	
sample	groups.	All	experimental	data	obtained	in	this	study	are	
represented	by	the	mean	and	SD	of	the	mean	(±SD),	and	statisti-
cal	 analyses	 were	 conducted	 considering	 a	 minimal	 statistical	
significance	(α)	at	5%	(p < 0.05).
resUlTs





fibroblast-like	 morphology,	 differentiation	 into	 mesodermal	
lineages	 (i.e.,	 adipocytes,	 chondrocytes,	 and	 osteoblasts),	 high	
proliferation	 index,	 and	 a	 distinctive	 immunophenotype	 with	
classical	MSCs	features	(Figure	S1	 in	Supplementary	Material).	
On	the	other	hand,	MVs	secreted	by	MSCs	displayed	spheroid	
morphology,	had	 small	 size	 (≈125 nm),	 exhibited	positivity	 to	
MSC	(i.e.,	CD105,	CD90,	and	CD44),	exosomes	(i.e.,	CD9	and	
CD63),	 and	 surface	 markers,	 and	 internally	 had	 the	 presence	
of	 miRNAs	 (<22  nt)	 and	 their	 biogenesis	 machinery	 (Dicer,	
Drosha,	and	Argonaut	2)	(Figure	S2	in	Supplementary	Material).	
Subsequently,	 we	 assessed	 the	 repair	 potential	 of	 MSCs	 and	
MSC-MV	treatment	 in	a	 toxic	model	of	AKI.	 Interestingly,	we	
demonstrated	 in  vivo	 after	 cisplatin	 administration	 that	 injec-




FigUre 1 | Msc and MV treatments promote tissue recovery. (a,b) Evaluation of weight loss; (c,D) determination of injury score; (e) serum creatinine levels; 
and (F) serum urea levels (*p < 0.05 compared with the saline/control group and &p < 0.05 compared with the cisplatin group). Cis, cisplatin; MSC, mesenchymal 
stromal cell; MVs, microvesicles.
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FigUre 2 | continued
(Continued)
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by	 reduction	of	 apoptosis	 index	 (active	 caspase	 3	 and	TUNEL	
assays)	and	interstitial	extracellular	matrix	deposition	(Sirius	red	
staining)	(Figure	S3	in	Supplementary	Material).
Msc and Msc-MV Therapies Modulate a 
set of prosurvival Molecules
In	 an	 attempt	 to	 investigate	 the	beneficial	 therapeutic	 effect	 of	
MSCs,	we	analyzed	in vivo	the	tissue	expression	of	molecules	that	




to	 damage	 group	 alone	 (cisplatin)	 (Figures  2A–C).	Moreover,	
the	MSC	and	MV	infusion	decreased	the	renal	oxidative	stress	
by	 enhancing	 anti-oxidant	 enzymes	 levels	 (e.g.,	 GSH/GSSG	
FigUre 2 |  injury- and protective-related molecules are modulated after Msc or MV treatments. (a) Serum lactate levels; (b) Kim-1 expression, a 
renal damage marker; (c) BCL-2/Bax ratio; (D) glutathione reduced (GSH) and oxidized (GSSG) ratio (GSH/GSSG); (e) expression of heme oxygenase 1 
(HO-1); (F) tissue levels of nitric oxide (NO); (g) expression of hepatocyte growth factor; (h) expression of vascular endothelial growth factor; (i) expression of 
insulin-like growth factor type 1 (IGF); (J) serum levels of interferon gamma (IFN-γ); (K) serum levels of interleukin 2; (l) serum levels of tumor necrosis factor α 
(TNF-α); (M) serum levels of interleukin 10; (n) serum levels of interleukin 4; (O) serum levels of interleukin 17, and (p,Q) protein expression of IKK-α kinase 
(*p < 0.05 compared with the saline/control group and &p < 0.05 compared with the cisplatin group). Cis, cisplatin; MSC, mesenchymal stromal cell; MVs, 
microvesicles.
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ratio	and	HO-1)	and	 reducing	 free	 radicals	presence	 (i.e.,	NO;	












Msc and Msc-MV Treatments promote In 




in  vitro	 co-culture	 assays,	 we	 observed	 after	 cisplatin	 stimulus	






Msc Treatment Modulates the global 
mirna profile in renal Tissue
In	 search	 for	 precise	 molecular	 mechanisms	 involved	 in	 the	
MSC-mediated	 cytoprotection,	we	analyzed	 the	global	miRNA	
profile	 changes	 in	 the	 renal	 tissue	 submitted	 to	 toxic	 injury	
alone	 or	 treated	 with	MSCs	 (Figure  4A).	We	 detected	 a	 total	
of	 528	 miRNAs	 expressed	 in	 common	 between	 all	 the	 tested	
conditions	 (Figure  4A;	 Figure	 S1	 in	 Supplementary	Material),	
in	 which	 39	 were	 upregulated	 and	 37	 were	 downregulated	 in	
the	 cisplatin	 condition	 when	 compared	 with	 saline	 at	 a	 fold	
change	 ≥3	 (Figures  4B,D).	 After	 MSC	 therapy,	 50	 miRNAs	
were	 upregulated	 and	 11	miRNAs	 were	 downregulated	 in	 the	
cisplatin + MSCs	condition	when	compared	with	cisplatin	alone,	
considering	a	fold	change	≥3	(Figure 4B).	Further,	we	observed	
that	 the	 proteins	 related	 to	 miRNA	 biogenesis	 (e.g.,	 Dicer,	
Drosha,	and	Argonaut	2)	were	all	modulated	during	toxic	injury,	
and	after	MSC	administration,	they	had	their	physiologic	levels	
re-established	 (Figure  4C).	 These	 results	 were	 complemented	
by	 miRNA	 amount	 analysis,	 which	 showed	 higher	 miRNA	
levels	 during	 injury	 process	 and	 lower	 levels	 after	MSC	 treat-
ment	(Figure	S4A	in	Supplementary	Material).	Additionally,	we	
FigUre 3 | continued
(Continued )
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FigUre 3 | Msc and MV treatment promoted cell recovery (a) Evaluation of cell death, apoptosis (Annexin V), and the necrosis (7-AAD) index;  
(b) determination of cell proliferation score (Cell Trace Ratio); and (c) analysis of oxidative stress and superoxide anion radical activity (O2
⋅−) (*p < 0.05 compared 
with the saline/control group and &p < 0.05 compared with the cisplatin group). Cis, cisplatin; MSC, mesenchymal stromal cell; MVs, microvesicles; Tub, murine 
renal tubular epithelial cell line MM55.K.
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observed	that	the	differential	changes	in	the	miRNA	signatures	
were	 associated	 with	 a	 broad	 modulation	 of	 specific	 miRNAs	






92a*,	 miR-292-3p,	 miR-673-5p,	 and	 miR-1190	 were	 the	 most	








looked	 for	biological	pathways	 that	were	 significantly	enriched	
with	those	genes.	Thus,	with	this	approach,	we	found	signaling	
pathways	related	to	tissue	repair	and	homeostasis	recovery,	such	
as	 regulation	 of	 actin,	 axon	 guidance,	 ErbB,	 P13K-Akt,	 Wnt,	








a	 presence	 of	 intrinsic	 regulatory	 mechanism	 (Figure  4F).	
In	 attempt	 to	 verify	 if	 the	miRNAs	 differentially	 expressed	 in	
renal	 tissues	were	 directly	 transferred	 by	MVs,	we	 carried	 out	
a	 miRNAs	 profile	 of	 MVs	 and	 MSCs	 and	 detected	 a	 higher	
number	of	miRNAs	upregulated	in	MVs	than	MSCs	(Figure	S5A	





Material).	These	findings	 suggest	 that	MVs	 and	MSCs	did	not	
share	the	same	miRNA	profile	and	its	effect	in	the	renal	tissue	can	
be	conducted	by	an	indirect	regulatory	process.
an integrative network analysis revealed 
the role of specific mirnas in aKi and in 
cytoprotection promoted by Mscs
In	order	to	identify	some	biological	functions	attributed	to	MSC	
renoprotection,	 we	 carried	 out	 an	 in  silico	 analysis	 with	 the	
most	 upregulated	 and	 downregulated	miRNAs	 in	 the	 cisplatin	
condition	compared	to	saline	and	connected	these	miRNAs	with	
previously	 described	 differentially	 expressed	 genes	which	were	
associated	 to	 cisplatin	 damage	 in	 renal	 tissues	 (Figure	 S6A	 in	
Supplementary	Material)	 (23,	24).	 After	 cisplatin	 intervention,	
we	observed	 that	 the	upregulated	 and	downregulated	miRNAs	
(red/green	triangles)	in	renal	tissues	were	strongly	integrated	in	
the	network,	considering	that	the	top	miRNAs	in	terms	of	fold	
change	 (yellow	 border	 triangles)	 showed	 interactions	with	 key	
molecules	altered	in	kidney	injury	(blue	and	orange	rectangles)	
(Figure	 S6A	 in	 Supplementary	 Material).	 Moreover,	 using	 a	
functional	and	enrichment	approach,	we	verified	in	this	miRNA–
mRNA	 network	 that	 the	 top	 miRNAs	 in	 fold	 change	 (yellow	
border	triangles)	also	interacted	with	specific	genes	involved	in	
TGF-β/Wnt	 (purple	 border	 rectangles)	 and	 fibrosis/epithelial–
mesenchymal	 transition	 (EMT)	 (orange	 rectangles)	 signaling	
pathways	(Figure	S6A	in	Supplementary	Material).	Furthermore,	
to	 heighten	 our	 inference	 analysis,	 we	 compared	 in	 a	 Venn	
diagram	 all	 the	 miRNA	 profiles	 and	 selected	 the	 10	 miRNAs	
FigUre 4 | The global mirna signature of renal tissues after Msc treatment.  
(Continued )
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FigUre 5 | mirna–mrna network in cytoprotection induced by Mscs. (a) MSCs-modulated network showing the interactions between miRNAs modulated 
by MSCs and putative targets genes interacting with at least two of these altered miRNAs, and (b) Venn diagrams depicting overlapping miRNA target genes 
obtained from three microRNA target prediction tools (TargetScan, miRanda, and miRDB) and a list of overlapping potential target genes for the top two differentially 
expressed miRNAs in the MSCs-modulated network (i.e., miR-141 and miR-377). Upregulated and downregulated miRNAs are represented, respectively, as red 
and green triangles. The top miRNAs in terms of fold changes had their border colors altered to yellow. Genes previously linked to fibrosis or epithelial–mesenchymal 
transition are represented as orange rectangles. Genes that were previously related to the TGF-β or Wnt pathways additionally had their border colors altered to 
purple and unrelated genes are represented in blue rectangles. Cis, cisplatin; MSCs, mesenchymal stromal cells; MVs, microvesicles.
(a) Heat map analysis of miRNA profile for all comparisons; (b) scatter plots representing the differentially expressed miRNAs with a fold change ≥3: (i) cisplatin in 
comparison to saline and (ii) cisplatin + MSC in comparison with cisplatin alone; (c) expression levels of proteins involved in miRNA biogenesis (Dicer 1, Drosha, and 
Argonaut 2); (D) bar plot of differentially expressed miRNAs with a fold change ≥3 at each comparison; (e) signaling pathways associated to genes predicted to be 
target of the top differentially expressed miRNAs; and (F) gene ontology analysis of biological processes linked to the top regulated miRNAs for all comparisons 
(*p < 0.05 compared with the saline/control group and &p < 0.05 compared with the cisplatin group). Cis, cisplatin; MSC, mesenchymal stromal cell; MVs, 
microvesicles.
FigUre 4 | continued
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(overlapping*)	that	were	exclusively	related	to	MSC	cytoprotec-
tion	 (Figure	 S6B	 in	 Supplementary	Material).	 Interestingly,	we	
also	 identified	 in	 this	 overlap	 two	miRNAs	 (i.e.,	miR-141	 and	
miR-377)	 that	 were	 inversely	 regulated	 between	 the	 “injury 
profile”	(Cis	vs.	Saline)	vs.	the	“treatment profile”	(Cis + MSC	vs.	
Cis)	(Figure 4D;	Figure	S6B	in	Supplementary	Material).	After,	
using	 these	 10	 pre-selected	miRNAs,	we	 constructed	 a	 second	
miRNA–mRNA	 network	 (“regulatory network”)	 and	 identified	
their	 corresponding	 predicted	 target	 genes	 (Figure  5A).	Then,	
we	 selected	 only	 the	 genes	 that	 were	 targeted	 by	 at	 least	 two	
miRNAs	in	order	to	visualize	the	most	relevant	miRNA–mRNA	
interactions	 (Figure  5A).	 In	 this	 second	 regulatory	 network,	
the	most	connected	miRNAs	were	over	again	the	miR-141	and	
miR-377	 (yellow	 border	 triangles)	 (Figure  5A).	 Subsequently,	
after	 enrichment	 analysis,	 we	 extracted	 semantic	 relationships	
between	these	miRNAs	and	again	verified	connection	with	genes	
related	to	the	TGF-β/Wnt	(purple	border	rectangles)	and	fibro-
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mirnas actively participate in Tissue 
injury and repair during aKi
To	validate	the	participation	of	miR-377	and	miR-141	in	tissue	
injury	 and	 repair,	we	 evaluated	 the	dynamic	 expression	of	 the	
precursor	and	mature	 forms	of	 these	miRNAs.	Cisplatin	 treat-
ment	 in  vivo	 increased	 both	 mature	 and	 pre-miR-377	 levels,	
proportionally	to	the	damage	severity	(Figure 6A).	Conversely,	
the	 renal	 tissue	 expression	 of	 both	 mature	 and	 pre-miR-141	





141	 in	 renal	 tissues	 submitted	 to	 toxic	 injury	 (Figures  6A,B).	
Interestingly,	 the	 detection	 of	 the	 pre-miR-377	 in	 early	 stages	
of	 the	 renal	 tissue	 injury	 suggests	 that	 its	 expression	 could	 be	
used	as	a	potential	marker	of	AKI	(Figure 6A).	Concordantly,	
we	 observed	 similar	 results	 using	 tubular	 cells	 in  vitro,	 which	




decrease	miR-377	 expression	 and	 increase	 the	miR-141	 levels	
when	compared	to	cisplatin-treated	cells	alone	(Figures 6C,D).	
According	 to	 the	damage	 severity,	we	 also	 observed	 in  vitro	 a	
premature	 expression	 of	 pre-miR-377	 than	 its	 mature	 form	
(miR-377),	whereas	the	pre-miR-141	expression	remained	unal-
tered	(Figures 6C,D).	For	elucidating	the	incorporation	process	
of	MVs	 by	 tubular	 epithelial	 cells,	we	 added	pre-stained	MVs	
suspensions	 (MVs	 labeled	with	fluorescent	 red	dye)	 to	 injured	
tubular	cells	cultures	(cultured	with	cisplatin)	and	analyzed	its	
progressive	 incorporation	 per	 24  h	 in	 a	 time-lapse	 assay.	We	
observed	that	MVs,	although	in	aggregated	status,	are	internal-
ized	by	epithelial	tubular	cells	(dim	red	dots	and	black	arrows)	
with	 predominant	 localization	 in	 the	 cytoplasm	 (Figure  6E;	
Movie	S3	in	Supplementary	Material).
The mirna–mrna interaction plays a 
Fundamental role in Msc-Mediated 
protection
To	investigate	the	role	of	miRNA–mRNA	interactions	on	kidney	
injury	progression	 and	 tissue	 recover	 after	MSC	 treatment,	we	






correspondent	 target	 molecules	 (Figure	 S7	 in	 Supplementary	
Material).	 Then,	 we	 observed	 in	 tubular	 cells	 submitted	 to	
cisplatin	 treatment	 a	 protection	 against	 cell	 death	 (reduction	
in	 apoptosis/active	 caspase-3	 and	 necrosis/7-AAD	 expression	
levels)	 only	 in	 cells	 incubated	 with	 inhibitors	 of	 miR-21	 and	
miR-377	 (Figure  7A).	 Complementary,	 the	 intracellular	 level	
of	 anion	 superoxide	 (O2
− ,	 a	 stress	 oxidative	 radical)	 decreased	
only	 in	 cells	 treated	 with	 inhibitors	 of	 miR-21	 and	 miR-377	
(Figure 7B).	By	contrast,	the	use	of	miR-880	and	miR-141	mim-
ics,	which	were	 elevated	 in	 tissues	 treated	with	MSCs,	 did	not	
show	 any	 direct	 protective	 effect	 on	 tubular	 cells	 submitted	 to	
toxic	injury	(Figures 7A,B).	In	addition,	the	 in vitro	 inhibition	
of	miR-377	 in	 tubular	 epithelial	 cells	 promoted	 an	 increase	 in	
the	 expression	 of	 cytoprotective	 genes	 (i.e.,	 BCL-2	 and	HO-1;	
Figures	 S8A,B	 in	 Supplementary	Material)	 and	 a	 reduction	 in	
damage-related	molecules	(i.e.,	Kim-1	and	iNOS;	Figures	S8C,D	
in	Supplementary	Material).	The	absence	of	any	significant	effects	
in	 the	 control	 (cells	 without	 cisplatin	 stimulus),	 the	 negative	
control	 (cells	 only	 exposed	 to	 transfection	 reagents),	 and	 the	
scrambled	oligos	groups	(miRNA	control,	cells	treated	with	not	
associated	miRNAs)	 corroborated	 the	 relevance	 of	 our	 results	
(Figures  7A,B;	 Figures	 S7A–D	 and	 S8A–D	 in	 Supplementary	
Material).	 In	 sequence,	 we	 selected	 potential	 target	 genes	 for	
miR-141	 (i.e.,	 Ulk2)	 and	 miR-377	 (i.e.,	 Cul1)	 and	 confirmed	
in  vitro	 and	 in  vivo	 their	 inverse	 relationships.	 Specifically,	we	
identified	 in  vitro	 that	Ulk2	 expression	 increased	under	 injury	
conditions	but	after	MVs	treatment	or	miR-141	overexpression	
had	 its	 levels	 decreased	 when	 compared	 to	 cisplatin-treated	
cells	 alone	 (Figure  7C).	These	 results	 were	 further	 confirmed	
in  vivo	 by	demonstrating	 that	 the	Ulk2	 levels	were	 elevated	 in	




















tionally	modulate	 the	molecular	 pattern	 in	 injured	 renal	 cells.	
Initially,	using	an	experimental	model	of	cisplatin-induced	AKI,	
FigUre 6 | Kinetics of expression of the top differentially expressed pre- and mature mirnas after Msc or MV treatments and MVs incorporation. 
(a) Expression of mature and pre-miR-377 in renal tissues with progressive damage by cisplatin; (b) expression of mature and pre-miRNA-141 in renal tissues with 
progressive damage by cisplatin; (c) expression of mature and pre-miR-377 in MM55.K tubular cells with progressive damage by cisplatin and MVs treatment; (D) 
expression of mature and pre-miR-141 in MM55.K tubular cells with progressive damage by cisplatin and MVs treatment; and (e) progressive time-course assay of 
in vitro MVs incorporation (dim red dots and black arrows) into tubular epithelial cells per 24 h, also demonstrated in Movie S3 in Supplementary Material (*p < 0.05 
compared with the saline/control group and &p < 0.05 compared with the cisplatin treatment, 15 and 20 mg/kg, 24 and 48 h). Cis, cisplatin; MSC, mesenchymal 
stromal cell; MVs, microvesicles.
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FigUre 7 | Functional validation of differentially expressed mirnas and their predicted targets.  
(Continued )
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(a) Evaluation of cell death frequency in MM55.K cells submitted to toxic injury with overexpression of miR-141 and miR-880 or silencing of miR-377 and miR-21 
expressions; (b) evaluation of oxidative stress in MM55.K cells submitted to toxic injury with overexpression of miR-141 and miR-880 or silencing of miR-377 and 
miR-21 expressions; (c) validation in vitro and in vivo of the potential target of miR-141 (Ulk2), and (D) validation in vitro and in vivo of the potential target of miR-377 
(Cul 1) (*p < 0.05 compared with the saline/control group and &p < 0.05 compared with the cisplatin group). Cis, cisplatin; MSC, mesenchymal stromal cell; MVs, 
microvesicles; Tub, renal tubular cells.
FigUre 7 | continued
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we	demonstrated	in vivo	and	in vitro	that	MVs,	although	by	dis-
tinct	mechanisms,	mimic	the	beneficial	effects	of	MSC	treatment	
modulating	 a	 prosurvival	 program	 and	 inhibiting	 cell	 death.	
Furthermore,	we	identified	a	prominent	participation	of	miRNAs	
as	main	protagonists	in	the	regulation	of	this	protective	effect.
In	 this	 sense,	 the	 miRNA	 profile	 has	 been	 characterized	




MVs-derived	 miRNAs.	 A	 recent	 work	 have	 conducted	 a	 GO	




lular	 differentiation,	 and	 cell	 survival	 (6).	 In	 fact,	 we	 showed	
here,	in vitro	and	in vivo,	that	markers	related	to	cytoprotection,	






These	 pathways	 play	 an	 essential	 role	 in	 tissue	 recover	 and	
development,	 as	 well	 as	 coordinate	 cellular	 health	 physiology.	
Indeed,	a	previous	study	from	our	group	already	demonstrated	
the	participation	of	MAPK,	ErbB,	and	Wnt	signaling	pathways	
during	 renal	 damage	 progression	 and	 their	 modulation	 after	
treatment	with	cytoprotective	and	anti-oxidant	molecules	 (28).	
Moreover,	 different	 studies	 have	 established	 an	 interesting	
interplay	 between	 the	 Notch–PI3K/Akt	 and	 mTOR–PI3K/Akt	
pathways	in	the	regulation	of	renal	cells	physiology	(29–31).	In	
line	 with	 this	 evidence,	 our	 results	 here	 demonstrated	 a	 strict	
association	between	differentially	modulated	miRNAs	with	regu-
latory	pathways	linked	to	positive	modulation	of	transcription-




had	 been	 previously	 linked	 to	 cisplatin	 damage.	 Interestingly,	
this	first	miRNA–mRNA	network,	“injured network,”	 related	 to	
toxic	injury	was	mainly	associated	with	alterations	in	TGF-β/Wnt	
and	fibrosis/EMT	signaling	pathways.	Subsequently,	our	second	
mRNA–miRNA	 network,	 “regulatory network,”	 which	 was	
comprised	by	10	pre-selected	miRNAs	found	in	the	overlapping	
(Figure	 S6B	 in	 Supplementary	Material),	 showed	 again	 a	 close	
link	between	these	miRNAs	with	genes	enriched	in	the	TGF-β/









considering	 a	 context	 of	 toxic	AKI,	 the	 search	 for	Wnt/TGF-β	
related	targets	may	be	an	interesting	strategy	to	understand	how	
MSCs	elicit	their	therapeutic	properties.
Complementarily,	 the	 use	 of	 miRNA–mRNA	 network	
analysis	allowed	us	to	understand,	in	a	systematic	and	integrative	
perspective,	how	miRNAs	are	linked	to	their	specific	target	genes.	
Additionally,	 we	 identified	miR-377	 and	miR-141	 as	 the	most	
connected	miRNAs	in	the	MSC-modulated	network	(regulatory 
network),	 thereby	 indicating	 their	eminent	participation	 in	 the	







particular,	 miR-377	 is	 overexpressed	 in	 renal	 chronic	 disease	
and	 its	 expression	 is	 associated	with	 fibronectin	 accumulation	
(37).	 In	fact,	TGF-β	expression	positively	regulates	miR-377	in	
diabetic	nephropathy	(38).	Moreover,	miR-377	promotes	matrix	
deposition	 and	 thereby	 directly	 contributes	 to	 pro-fibrotic	
response	elicited	by	TGF-β	(39).	Conversely,	the	miR-141	levels	
are	 reduced	 in	 renal	disease	 and	 cancer	 (40,	41).	Additionally,	




underlying	 to	 MSC	 protection,	 considering	 here	 a	 context	 of	
cisplatin-induced	kidney	injury.
To	document	this	interesting	connection,	we	identified	puta-








some	 instability	 (43,	44).	The	essential	 function	of	Ulk2	 is	not	
entirely	elucidated,	but	studies	have	suggested	its	evolutionarily	
17
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may	 underlie	 some	 of	 the	 protective	 effects	 induced	 by	MSCs	
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main	 findings	 illustrated	 here	may	 contribute	 substantially	 for	
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MOVie s1 | Movement pattern visualization of animal treated with 
cisplatin (injured group). Movie file (.avi).
MOVie s2 | Movement pattern visualization of animal treated with 
cisplatin and Mscs (treated group). Movie file (.avi).
MOVie s3 | In vitro MVs incorporation into tubular epithelial cells. Movie 
file (.avi).
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